Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEAST: Redox PSC Pilot Study in PSC
NCT07898839Phase 2Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2027
- Primary completion
- Dec 2028
01
Overview
A Phase 2 trial of alpha-lipoic acid, acetylcysteine, nicotinamide riboside, liquid metformin (Aspargo Labs) in Primary Sclerosing Cholangitis (PSC), sponsored by Brigham and Women's Hospital. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
alpha-lipoic acidacetylcysteinenicotinamide ribosideliquid metformin (Aspargo Labs)
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT07898839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07898839.